Page last updated: 2024-11-10

paricalcitol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5281104
CHEMBL ID1200622
CHEBI ID7931
SCHEMBL ID3655
MeSH IDM0224873

Synonyms (74)

Synonym
BIDD:GT0330
HY-50919
6702d36og5 ,
unii-6702d36og5
paricalcitol [usan:usp:inn]
gtpl2791
paracalcin
abt-358
(1alpha.3beta,7e,22e)-19-nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol
(7e,22e)-19-nor-9,10-secoergosta-5,7,22-triene-1alpha,3beta,25-triol
compound-49510
hsdb 7360
paricalcitol [usan]
compound 49510
19-nor-1-alpha,25-dihydroxyvitamin d2
19-nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol, (1alpha,3beta,7e,22e)-
zemplar
19-nor-1,25-(oh)2d2
CHEBI:7931 ,
(1r,3r,7e)-17beta-[(2r,3e,5s)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-9,10-secoestra-5,7-diene-1,3-diol
19-nor-1alpha,25-dihydroxyvitamin d2
paricalcitol ,
C08127
131918-61-1
DB00910
zemplar (tn)
paricalcitol (jan/usp/inn)
D00930
CHEMBL1200622
AKOS005145562
LMST04030163
NCGC00182706-01
(1r,3r)-5-[(2e)-2-[(1r,3as,7ar)-1-[(e,2r,5s)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol
tox21_112987
cas-131918-61-1
dtxsid4048640 ,
dtxcid7028566
BCP9001050
paricalcitol [jan]
paricalcitol [mi]
paricalcitol [orange book]
paricalcitol [hsdb]
paricalcitol [who-dd]
paricalcitol [vandf]
paricalcitol [usp impurity]
(7e,22e)-19-nor-9,10-secoergosta-5,7,22-triene-1.alpha.,3.beta.,25-triol
(1.alpha.3.beta.,7e,22e)-19-nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol
paricalcitol [usp-rs]
paricalcitol [mart.]
paricalcitol [usp monograph]
CS-0705
S6681
SCHEMBL3655
BPKAHTKRCLCHEA-UBFJEZKGSA-N
(1r,3r,5z)-5-[(2e)-2-[(1r,3as,7ar)-octahydro-1-[(1r,2e,4s)-5-hydroxy-1,4,5-trimethyl-2-hexen-1-yl]-7a-methyl-4h-inden-4-ylidene]ethylidene]-1,3-cyclohexanediol
(1r,3r)-5-(2-((1r,3as,7ar,e)-1-((2r,5s,e)-6-hydroxy-5,6-dimethylhept-3-en-2-yl)-7a-methyloctahydro-4h-inden-4-ylidene)ethylidene)cyclohexane-1,3-diol ,
(1alpha,3beta,7e,22e)-19-nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol
bdbm233195
Q155746
AMY2878
1,3-cyclohexanediol, 5-[(2e)-2-[(1r,3as,7ar)-octahydro-1-[(1r,2e,4s)-5-hydroxy-1,4,5-trimethyl-2-hexen-1-yl]-7a-methyl-4h-inden-4-ylidene]ethylidene]-, (1r,3r,5z)-
EX-A4434
A937163
MS-27260
paricalcitolum
h05bx02
(1alpha3beta,7e,22e)-19-nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol
paricalcitol (usan:usp:inn)
paricalcitol (usp-rs)
(1r,3r,7e)-17beta-((2r,3e,5s)-6-hydroxy-5,6-dimethylhept-3-en-2-yl)-9,10-secoestra-5,7-diene-1,3-diol
paricalcitol (mart.)
paricalcitol (usp impurity)
paricalcitol (usp monograph)
(1r,3r,7e,22e)-19-nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol

Research Excerpts

Overview

Paricalcitol (Pari) is a vitamin D2 analogue, which has been indicated to show anti-inflammatory activities in kidney and heart diseases. It is an effective therapy for secondary hyperparathyroidism in kidney transplant recipients.

ExcerptReferenceRelevance
"Paricalcitol is a vitamin D analog that is typically used for secondary hyperparathyroidism in patients with chronic kidney disease but may have some beneficial effect on DN."( Use of Paricalcitol as Adjunctive Therapy to Renin-Angiotensin-Aldosterone System Inhibition for Diabetic Nephropathy: A Systematic Review of the Literature.
Al-Makki, A; Schuster, A; Shepler, B, 2019
)
1.69
"Paricalcitol (Pari) is a vitamin D2 analogue, which has been indicated to show anti-inflammatory activities in kidney and heart diseases."( Paricalcitol improves experimental autoimmune encephalomyelitis (EAE) by suppressing inflammation via NF-κB signaling.
Fu, T; Qiao, L; Zhang, D, 2020
)
2.72
"Paricalcitol is an effective therapy for secondary hyperparathyroidism in kidney transplant recipients."( Effect of Paricalcitol on Bone Density After Kidney Transplantation: Analysis of 2 Transplant Centers.
Breza, J; Dedinská, I; Laca, L; Žilinská, Z, 2017
)
2.3
"Paricalcitol is a synthetic vitamin D2 agonist of the VDR approved for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD)."( Clinical Uses of 1,25-dihydroxy-19-nor-vitamin D(2) (Paricalcitol).
Ballarin, J; Bover, J; Cozzolino, M; Dasilva, I; Diaz-Encarnacion, MM; Furlano, M; Lloret, MJ, 2014
)
1.37
"Paricalcitol is an effective and well-tolerated treatment option for the control of iPTH levels in hemodialysis patients with sHPT. "( Paricalcitol treatment of secondary hyperparathyroidism in hemodialysis patients: a German-Austrian, single-arm, open-label, prospective, noninterventional, observational study.
Biggar, P; Graf, H; Ketteler, M; Klauser-Braun, R; Kovarik, J; Müller, HW; Seidinger, S; Veres, A, 2014
)
3.29
"Paricalcitol is an effective therapy for secondary hyperparathyroidism in kidney transplant recipients. "( Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
Acosta Martínez, Y; Borrego Utiel, FJ; Bravo Soto, JA; García Álvarez, T; González Carmelo, I; López Jiménez, V; Mazuecos Blanca, MA; Merino Pérez, MJ, 2015
)
2.26
"Paricalcitol is a vitamin D analogue that is safe."( Paricalcitol reduces basal and lipopolysaccharide-induced (LPS) TNF-alpha and IL-8 production by human peripheral blood mononuclear cells.
Antoniadi, G; Eleftheriadis, T; Galaktidou, G; Kartsios, C; Liakopoulos, V; Stefanidis, I, 2010
)
2.52
"Paricalcitol is a vitamin D analogue developed to overcome some of the limitations of calcitriol therapy."( Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism.
Abdul Gafor, AH; Loo, CY; Mohd, R; Norella, KC; Saidin, R; Shah, SA; Zainudin, S, 2009
)
1.36
"Paricalcitol is a new generation selective vitamin D receptor activator that lowers PTH levels by exerting a less hypercalcaemic and hyperphosphataemic effect."( Paricalcitol in secondary hyperparathyroidism and the survival benefit in patients with chronic kidney disease.
Al-Baaj, F; Al-Rifai, A; Yadav, P, 2011
)
2.53
"Paricalcitol is a synthetic vitamin D analogue acting on vitamin D receptor (VDR). "( The role of paricalcitol on proteinuria.
Alivanis, P; Aperis, G; Arvanitis, A; Paliouras, C; Zervos, A, 2011
)
2.19
"Paricalcitol is a vitamin D receptor activator with efficacy in the treatment of hyperparathyroidism that also has the minor side effects of hypercalcemia and hyperphosphatemia."( Effects of oral paricalcitol on hyperparathyroidism and proteinuria in peritoneal dialysis patients.
Cigarrán, S; Coronel, F; Gomis, A; Rodríguez-Cubillo, B, 2011
)
1.44
"Paricalcitol is a selective vitamin D receptor activator with an effect upon systemic inflammation and an inhibitory effect upon the renin-angiotensin-aldosterone system (RAAS)."( Changes in peritoneal membrane permeability and proteinuria in patients on peritoneal dialysis after treatment with paricalcitol − a preliminary study.
Cigarran, S; Coronel, F; Delgado, J; Delgado, P; Gomis, A; Herrero, JA; Rodríguez-Cubillo, B, 2012
)
1.31
"Paricalcitol is a selective VDR (vitamin D receptor) activator, used for targeted suppression of parathyroid glands."( [Vitamin D metabolism and current options for therapeutic activation of vitamin D receptor in patients with chronic kidney disease or renal failure].
Dusilová Sulková, S, 2012
)
1.1
"Paricalcitol (Zemplar) is a synthetic vitamin D(2) analogue that inhibits the secretion of parathyroid hormone (PTH) through binding to the vitamin D receptor. "( Paricalcitol: a review of its use in the management of secondary hyperparathyroidism.
Robinson, DM; Scott, LJ, 2005
)
3.21
"Paricalcitol (Zemplar) is a synthetic vitamin D2 analog that inhibits the secretion of parathyroid hormone (PTH) through binding to the vitamin D receptor. "( Spotlight on paricalcitol in secondary hyperparathyroidism.
Robinson, DM; Scott, LJ, 2005
)
2.14
"Paricalcitol is a less hypercalcemic vitamin D analog that has been shown to suppress secondary hyperparathyroidism and to prevent the associated histomorphometric changes in bone. "( Paricalcitol [19-nor-1,25-(OH)2D2] in the treatment of experimental renal bone disease.
Järvinen, TL; Jokihaara, J; Jolma, P; Kalliovalkama, J; Kannus, P; Kööbi, P; Niemelä, O; Pajamäki, I; Pörsti, I; Sievänen, H; Vuohelainen, T, 2006
)
3.22
"Paricalcitol is a new vitamin D analogue that is safe and effective in suppressing elevated concentrations of PTH in patients with established hyperparathyroidism who are maintained on chronic hemodialysis."( Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis.
Goldenberg, MM, 1999
)
2.47
"Paricalcitol is a vitamin D analog approved for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure. "( A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.
Acchiardo, SR; González, EA; Lindberg, J; Martin, KJ; Soltanek, C; Valdin, JR, 2001
)
1.99

Effects

Paricalcitol has demonstrated superiority to calcitriol with respect to parathyroid hormone suppression and calcium-phosphorus balance. It has proved effective to control secondary hyperparathyroidism in chronic kidney disease in both dialysed and non-dialysed patients.

ExcerptReferenceRelevance
"Paricalcitol has a tendency toward improving delayed hypersensitivity reactions, but did not have other proimmune effects."( A placebo-controlled trial to evaluate immunomodulatory effects of paricalcitol.
Ambrosius, WT; Batiuk, TD; Gassensmith, CM; Harezlak, J; Moe, SM; Murphy, CL; Russell, RR; Zekonis, M, 2001
)
1.27
"Paricalcitol has been proposed for the treatment of secondary hyperparathyroidism in patients with renal failure and vitamin D deficiency (VDD); however, VDD is related to a range of clinical complaints. "( Effects of Paricalcitol on Body Composition in Vitamin D-Deficient Rats.
Koohpeyma, F; Ranjbar Omrani, G; Saki, F; Zamani, A, 2021
)
2.45
"Paricalcitol has demonstrated superiority to calcitriol with respect to parathyroid hormone suppression and calcium-phosphorus balance."( Safety and tolerability of paricalcitol in patients with chronic kidney disease.
Dyer, CA, 2013
)
1.41
"Paricalcitol has proved effective to control secondary hyperparathyroidism in chronic kidney disease in both dialysed and non-dialysed patients, with a low hypercalcaemia incidence."( Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
Acosta Martínez, Y; Borrego Utiel, FJ; Bravo Soto, JA; García Álvarez, T; González Carmelo, I; López Jiménez, V; Mazuecos Blanca, MA; Merino Pérez, MJ, 2015
)
1.54
"Paricalcitol has recently been reported to have anticancer activity in prostate cancer."( 19-nor-1alpha,25-dihydroxyvitamin D(2) (paricalcitol): effects on clonal proliferation, differentiation, and apoptosis in human leukemic cell lines.
Dodge, WH; Kute, T; Molnár, I; Powell, BL; Schwartz, GG; Willingham, MC, 2003
)
1.31
"Paricalcitol has anticancer activity against myeloid leukemia, myeloma, and colon cancer cells that may be mediated through the VDR. "( Vitamin D2 analog 19-nor-1,25-dihydroxyvitamin D2: antitumor activity against leukemia, myeloma, and colon cancer cells.
Koeffler, HP; Kumagai, T; O'Kelly, J; Said, JW, 2003
)
1.76
"Paricalcitol has a tendency toward improving delayed hypersensitivity reactions, but did not have other proimmune effects."( A placebo-controlled trial to evaluate immunomodulatory effects of paricalcitol.
Ambrosius, WT; Batiuk, TD; Gassensmith, CM; Harezlak, J; Moe, SM; Murphy, CL; Russell, RR; Zekonis, M, 2001
)
1.27

Actions

ExcerptReferenceRelevance
"paricalcitol, efficiently suppress parathyroid hormone serum levels (PTH), but do not increase intestinal calcium absorption as much as calcitriol."( Calcium balance during calcitriol and paricalcitol administration in healthy humans.
Bommer, J; Diedrichs, L; Ding, R; Hafner, V; Heinrich, T; Mikus, G; Rutsch, C; Schmidt-Gayk, H; Walter-Sack, I, 2008
)
1.34

Treatment

Paricalcitol treatment for 12 weeks does not improve IR in patients with stage 3-4 CKD. The study found that VDR had a regulatory effect on the Wnt signaling pathway.

ExcerptReferenceRelevance
"Paricalcitol treatment might be profitable in regulating inflammatory and anticalcificant parameters, unmodified calcium or phosphorus seric levels and preserving kidney function in renal patients with no dialysis. "( Paricalcitol regulatory effect on inflammatory, fibrotic and anticalcificating parameters in renal patiente. Far beyond mineral bone disease regulation.
Aguilera Peralta, A; Gil Giraldo, Y; Salanova Villanueva, L; Santos Sánchez-Rey, B,
)
3.02
"Paricalcitol treatment restored villin, nephrin, and podocin protein levels that were downregulated upon DM induction, and reduced fibronectin protein level. "( The Therapeutic Effect of Active Vitamin D Supplementation in Preventing the Progression of Diabetic Nephropathy in a Diabetic Mouse Model.
Dahan, I; Farber, E; Hanut, A; Nakhoul, F; Nakhoul, N; Nakhoul, R; Salameh, G; Shagrawy, I; Tadmor, H; Thawko, T, 2020
)
2
"Paricalcitol treatment was associated with improved structural changes in type 1 diabetic mice including upregulation of vitamin D receptor expression, and decreased fibrosis markers such as fibronectin. "( The Therapeutic Effect of Active Vitamin D Supplementation in Preventing the Progression of Diabetic Nephropathy in a Diabetic Mouse Model.
Dahan, I; Farber, E; Hanut, A; Nakhoul, F; Nakhoul, N; Nakhoul, R; Salameh, G; Shagrawy, I; Tadmor, H; Thawko, T, 2020
)
2
"Paricalcitol treatment did not significantly affect the blood- or tissue levels of any other investigated inflammatory marker."( Exploring the potential effect of paricalcitol on markers of inflammation in de novo renal transplant recipients.
Aukrust, P; Dahle, DO; Eide, IA; Gatti, F; Hammarström, C; Haraldsen, G; Hartmann, A; Holdaas, H; Kasprzycka, M; Michelsen, AE; Midtvedt, K; Mjøen, G; Pihlstrøm, HK; Ueland, T; Wang, J, 2020
)
1.56
"Paricalcitol treatment reduced renal collagen I and renal interstitial fibrosis by decreasing the activation of the RAAS through renal changes in renin, angiotensin receptor 1 (ATR1) and ATR2 mRNAs levels and renal inflammation by decreasing renal inflammatory leucocytes (CD45), a desintegrin and metaloproteinase mRNA, transforming growth factor beta mRNA and protein, and maintaining E-cadherin mRNA levels."( Effects of calcitriol and paricalcitol on renal fibrosis in CKD.
Alonso-Montes, C; Cannata-Andía, JB; Carrillo-López, N; Dusso, AS; Fernández-Martín, JL; Fernández-Villabrille, S; García Gil-Albert, C; Martín-Carro, B; Martín-Vírgala, J; Martínez-Arias, L; Naves-Díaz, M; Palomo-Antequera, C; Panizo, S; Ruiz-Torres, MP, 2021
)
1.64
"Paricalcitol treatment suppressed the induction of these RAS components, whereas vitamin D deficiency enhanced the activation of the lung RAS."( Vitamin D suppresses bleomycin-induced pulmonary fibrosis by targeting the local renin-angiotensin system in the lung.
Chang, J; Du, J; Ge, X; Li, X; Li, YC; Liu, W; Nie, H; Sun, Y; Wei, X; Xun, Z, 2021
)
1.34
"Paricalcitol treatment lowered PTH levels (P = 0.01) but did not significantly reduce albuminuria (P = 0.76), change vascular parameters (PWV; P = 0.98, RHI; P = 0.33), or influence GFR (P = 0.57)."( Early introduction of oral paricalcitol in renal transplant recipients. An open-label randomized study.
Dahle, DO; Eide, IA; Gatti, F; Hammarström, C; Haraldsen, G; Hartmann, A; Holdaas, H; Kasprzycka, M; Midtvedt, K; Mjøen, G; Pihlstrøm, HK; Svensson, MHS; Wang, J, 2017
)
1.47
"Paricalcitol treatment for 12 weeks in patients with moderate CKD reduces cytokines and micro RNAs involved in atherosclerosis and inflammation. "( Vitamin D receptor activation reduces inflammatory cytokines and plasma MicroRNAs in moderate chronic kidney disease - a randomized trial.
Jacobson, SH; Lundahl, J; Lundwall, K; Mansouri, L; Moshfegh, A; Spaak, J, 2017
)
1.9
"Paricalcitol treatment resulted in the up-regulation of VDR and down-regulation of GSK-3β and β-catenin, indicating that VDR had a regulatory effect on the Wnt signaling pathway."( VDR Activation Reduces Proteinuria and High-Glucose-Induced Injury of Kidneys and Podocytes by Regulating Wnt Signaling Pathway.
Guo, J; He, M; Liu, Z; Lu, C; Wang, C; Yu, H; Zhang, F; Zhao, Z; Zhou, M, 2017
)
1.18
"Paricalcitol treatment for 12 weeks does not improve IR in patients with stage 3-4 CKD. "( Vitamin D receptor activation by paricalcitol and insulin resistance in CKD.
Curatola, G; Cutrupi, S; Mallamaci, F; Pizzini, P; Spoto, B; Tripepi, G; Zoccali, C, 2018
)
2.2
"Paricalcitol treatment, resulted in successful iPTH control. "( Treatment of secondary hyperparathyroidism with paricalcitol in patients with end-stage renal disease undergoing hemodialysis in Turkey: an observational study.
Akdag, Y; Ersoy, FF; Hoser, H; Kendir, C; Koc, H, 2019
)
2.21
"Paricalcitol treatment reduced parathormone (-75 pg/mL; 95% confidence interval, -90 to -60), whereas parathormone showed a small rise during placebo (21 pg/mL; 95% confidence interval, 5-36)."( Paricalcitol and endothelial function in chronic kidney disease trial.
Bolignano, D; Curatola, G; Cutrupi, S; Ghiadoni, L; Mallamaci, F; Panuccio, V; Pizzini, P; Politi, R; Thadhani, R; Tripepi, G; Tripepi, R; Versace, M; Zoccali, C, 2014
)
2.57
"Paricalcitol treatment resulted in a significantly increased frequency of CD8+ T cells showing a regulatory phenotype."( Paricalcitol reduces peritoneal fibrosis in mice through the activation of regulatory T cells and reduction in IL-17 production.
Aroeira, LS; Bellón, T; Fernández-Míllara, V; González-Mateo, GT; Liappas, G; López-Cabrera, M; Ruiz-Ortega, M; Selgas, R, 2014
)
2.57
"Paricalcitol treatment significantly reduced urinary albumin/creatinine ratio (UACR), 24-hour albuminuria (24hA), and 24-hour proteinuria (24hP)."( Proteinuria and Albuminuria During and After Paricalcitol Treatment in Chronic Kidney Disease Patients.
Bevc, S; Ekart, R; Hojs, N; Hojs, R, 2016
)
1.42
"Paricalcitol-treated patients showed a decrease in the methylation of the KLOTHO promoter with an increment in the ratio of un-methyated/methylated DNA, which was associated with an increase of KLOTHO gene expression levels and serum KLOTHO concentrations."( Effect of Paricalcitol on FGF-23 and Klotho in Kidney Transplant Recipients.
Donate-Correa, J; Henríquez-Palop, F; Martín-Núñez, E; Mora-Fernández, C; Muros-de-Fuentes, M; Navarro-González, JF; Pérez-Delgado, N, 2016
)
1.56
"Paricalcitol and combined treatment significantly (P < 0.01) reduced the level of fasting, postprandial blood glucose, homeostatic model assessment-insulin resistance, cardiac malondialdehyde and nitric oxide. "( Effect of Combination of Angiotensin-Converting Enzyme Inhibitors and Vitamin D Receptor Activators on Cardiac Oxidative Stress in Diabetic Rats.
Ali, TM; Askary, AE; Elsaid, AG; Mehanna, OM, 2016
)
1.88
"Paricalcitol treatment showed both benefits and harmful effects in uremic rats: in the large artery vasoconstriction was reduced but calcification increased, while in the small artery vasorelaxation via potassium channels was moderately improved but hypertrophic remodeling was aggravated."( Paricalcitol treatment and arterial tone in experimental renal insufficiency.
Eräranta, A; Karavalakis, E; Kööbi, P; Koskela, JK; Mustonen, J; Niemelä, O; Pörsti, I; Ruskoaho, H; Rysä, J; Vehmas, TI, 2008
)
3.23
"Paricalcitol treatment produced significant changes in urinary peptidome of kidney transplant patients. "( Effect of paricalcitol on the urinary peptidome of kidney transplant patients.
Bayés, B; Lauzurica, R; Navarro-Muñoz, M; Pastor, MC; Pérez, V; Romero, R; Sánchez, A, 2010
)
2.21
"Paricalcitol pretreatment improved renal function (decreased blood urea nitrogen and serum creatinine levels), tubular necrosis and apoptotic cell death in IRI-mice kidneys. "( Pretreatment with paricalcitol attenuates inflammation in ischemia-reperfusion injury via the up-regulation of cyclooxygenase-2 and prostaglandin E2.
Chang, YK; Choi, HS; Hong, SY; Hwang, HS; Jeon, BH; Kim, SH; Kim, SY; Lee, SJ; Park, CW; Park, KC; Yang, CW; Yang, KJ, 2013
)
2.17
"Paricalcitol treatment significantly reduces PTH levels in G1 at 3 months (P<.039)."( Double treatment with paricalcitol-associated calcifediol and cardiovascular risk biomarkers in haemodialysis.
Allende, N; Arias, M; García-Unzueta, MT; Izquierdo-Ortiz, MJ; López-Hoyos, M; Martín-de Francisco, ÁL; Piñera-Haces, C; Quintela, E; Toyos, C, 2013
)
1.43
"Paricalcitol-treated patients achieved a > or =50% reduction from baseline PTH significantly faster than did the calcitriol-treated patients (P = 0.025) and achieved a mean reduction of PTH into a desired therapeutic range (100 to 300 pg/mL) at approximately week 18, whereas the calcitriol-treated patients, as a group, were unable to achieve this range. "( Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism.
Amdahl, M; Batlle, D; Llach, F; Sprague, SM; Taccetta, C, 2003
)
3.2
"Paricalcitol treatment reduced PTH concentrations more rapidly with fewer sustained episodes of hypercalcemia and increased Ca x P product than calcitriol therapy."( Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism.
Amdahl, M; Batlle, D; Llach, F; Sprague, SM; Taccetta, C, 2003
)
3.2
"Paricalcitol-treated patients experienced fewer hospitalizations and hospital days per year when compared with calcitriol-treated patients. "( Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings.
Amdahl, M; Dobrez, DG; Marx, SE; Mathes, A; Melnick, JZ; Sprague, SM, 2004
)
3.21
"Paricalcitol treatment resulted in a significant reduction in serum alkaline phosphatase from 148+/-23 U/L to 101+/-14 U/L (P < 0.001) in patients treated for 12 wk compared with 120+/-9 U/L to 130+/-11 U/L (P=NS) in patients receiving placebo for 12 wk."( 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis.
Abboud, H; Gellens, M; González, EA; Hamm, LL; Lindberg, J; Martin, KJ, 1998
)
1.29
"no treatment); paricalcitol, 6.9 (significant vs."( Paricalcitol and cinacalcet have disparate actions on parathyroid oxyphil cell content in patients with chronic kidney disease.
Brown, AJ; Coyne, DW; Gupta, D; Miller, B; Ritter, C; Slatopolsky, E; Zheng, S, 2017
)
2.24
"Treatment with paricalcitol inhibited IS-induced apoptosis by regulating MAPK, NF-κB, and Akt signaling pathway in HK-2 cells."( Paricalcitol attenuates indoxyl sulfate-induced apoptosis through the inhibition of MAPK, Akt, and NF-kB activation in HK-2 cells.
Bae, EH; Choi, HI; Kim, SW; Ma, SK; Park, JS, 2019
)
2.31
"Treatment with paricalcitol started at mean dose of 1µg/day and lasted 18 months."( [Correction of secondary hyperparathyroidism with paricalcitol in renal transplant improves left ventricular hypertrophy].
Feriozzi, S; Imperato, G; Massimetti, C, 2019
)
1.11
"Treatment with paricalcitol reduces concentrations of ICAM-1 positive MPs. "( Changes in microparticle profiles by vitamin D receptor activation in chronic kidney disease - a randomized trial.
Jacobson, SH; Jörneskog, G; Lundwall, K; Mobarrez, F; Mörtberg, J; Spaak, J, 2019
)
0.87
"Pre-treatment with paricalcitol attenuated functional deterioration and histological damage in I/R induced AKI, and significantly decreased tissue neutrophil and macrophage infiltration and the levels of chemokines, the pro-inflammatory cytokine interleukin-6 (IL-6), and monocyte chemoattractant protein-1 (MCP-1). "( Renoprotective effect of paricalcitol via a modulation of the TLR4-NF-κB pathway in ischemia/reperfusion-induced acute kidney injury.
Cho, E; Cho, WY; Jo, SK; Kim, HK; Kim, MG; Kim, SC; Ko, YS; Lee, HY; Lee, JW, 2014
)
1.03
"Cotreatment with paricalcitol increased the protein levels of the epithelial cell marker and decreased those of mesenchymal markers compared with their levels in cells treated with TGF-β1 alone."( Paricalcitol ameliorates epithelial-to-mesenchymal transition in the peritoneal mesothelium.
Cho, KH; Do, JY; Kang, SH; Kim, SO; Park, JW; Yoon, KW, 2014
)
2.17
"Treatment with paricalcitol at this dose and duration did not affect brachial artery FMD or biomarkers of inflammation and oxidative stress. "( Effect of paricalcitol on endothelial function and inflammation in type 2 diabetes and chronic kidney disease.
Bajwa, MA; Dandona, P; Desouza, C; Fang-Hollingsworth, Y; Fonseca, VA; Ghanim, H; Goldfine, AB; Jo, C; Raghavan, V; Thethi, TK; Umpierrez, G; Weir, M, 2015
)
1.17
"Treatment with paricalcitol suppressed the TNF-α-induced increase in the protein expression of intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and fractalkine in endothelial cells."( Paricalcitol attenuates lipopolysaccharide-induced myocardial inflammation by regulating the NF-κB signaling pathway.
Jung, YJ; Kang, KP; Kim, W; Lee, AS; Lee, S; Park, SK; Thanh, TN, 2016
)
2.22
"Treatment with paricalcitol (0.333 microg/kg) increased serum phosphorus at Weeks 2 and 6; these changes were not different from those observed in 5/6 NX rats."( Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats.
Bolin, A; Dixon, D; Koch, K; Ma, J; Nakane, M; Noonan, W; Reinhart, G, 2008
)
0.69
"Treatment with paricalcitol and enalapril alone or in combination protected the inflammatory and oxidative endothelial injury of the aorta in atherosclerotic mice."( Effects of paricalcitol and enalapril on atherosclerotic injury in mouse aortas.
Ferder, L; Husain, K; Isidro, A; Suarez, E, 2010
)
1.09
"Treatment with paricalcitol, a selective vitamin D receptor (VDR) activator, has shown benefits in these patients by adequately reducing PTH levels with minimal changes in serum calcium and phosphorus."( Effectiveness of treatment with oral paricalcitol in patients with pre-dialysis chronic kidney disease.
Cerezo Morales, S; Hervás Sánchez, JG; Polo Moyano, A; Prados Garrido, MD, 2011
)
0.98
"Treatment with paricalcitol is effective in controlling secondary hyperparathyroidism in non-dialysed patients with a wide safety margin."( Effectiveness of treatment with oral paricalcitol in patients with pre-dialysis chronic kidney disease.
Cerezo Morales, S; Hervás Sánchez, JG; Polo Moyano, A; Prados Garrido, MD, 2011
)
1
"Treatment with paricalcitol reduced parathyroid hormone levels within 4 weeks and maintained levels within the normal range throughout the study duration. "( Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial.
Agarwal, R; Andress, D; Appelbaum, E; Bhan, I; Cannata, J; Chang, Y; Lloyd-Jones, D; Manning, WJ; Pachika, A; Packham, D; Pritchett, Y; Shah, A; Singh, B; Solomon, SD; Tamez, H; Thadhani, R; Thompson, BT; Wanner, C; Wenger, J; Zehnder, D; Zhang, W; Zoccali, C, 2012
)
0.73
"Both treatment with paricalcitol and with calcifediol produced a significant decrease in levels of IL-8 (P<.001), a known inflammatory marker, drawing attention to a trend towards better response to erythropoiesis-stimulating agents (ESAs), possibly related to the decrease in inflammation."( Double treatment with paricalcitol-associated calcifediol and cardiovascular risk biomarkers in haemodialysis.
Allende, N; Arias, M; García-Unzueta, MT; Izquierdo-Ortiz, MJ; López-Hoyos, M; Martín-de Francisco, ÁL; Piñera-Haces, C; Quintela, E; Toyos, C, 2013
)
1.02
"Treatment with paricalcitol was superior to placebo treatment beginning at week 1. "( Topical paricalcitol (19-nor-1 alpha,25-dihydroxyvitamin D2) is a novel, safe and effective treatment for plaque psoriasis: a pilot study.
Durakovic, C; Holick, MF; Ray, S, 2004
)
1.11
"Treatment with paricalcitol injection based on degree of secondary hyperparathyroidism incurred no greater risk for hypercalcemia and achieved meaningful therapeutic results with fewer dose adjustments than dosing based on patient body weight."( Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study.
Amdahl, M; González, E; Lindberg, JS; Llach, F; Malhotra, K; Martin, KJ; Taccetta, C, 2001
)
2.09

Toxicity

Paricalcitol suppresses iPTH and lowers proteinuria in patients with stage 2-5 CKD without an increased risk of adverse events. Adverse events were higher in children who received placebo.

ExcerptReferenceRelevance
" There was no significant difference in adverse events between the paricalcitol and placebo-treated groups."( 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis.
Abboud, H; Gellens, M; González, EA; Hamm, LL; Lindberg, J; Martin, KJ, 1998
)
0.81
" Adverse events that were considered by the investigator to have a possible."( A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.
Acchiardo, SR; González, EA; Lindberg, J; Martin, KJ; Soltanek, C; Valdin, JR, 2001
)
0.55
"This long-term study of paricalcitol demonstrates that it rapidly and effectively suppresses iPTH levels in a wide spectrum of ESRD patients and caused no unexpected adverse events."( A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.
Acchiardo, SR; González, EA; Lindberg, J; Martin, KJ; Soltanek, C; Valdin, JR, 2001
)
0.86
" Topical active vitamin D compounds have proven to be both safe and effective for treating psoriasis."( Topical paricalcitol (19-nor-1 alpha,25-dihydroxyvitamin D2) is a novel, safe and effective treatment for plaque psoriasis: a pilot study.
Durakovic, C; Holick, MF; Ray, S, 2004
)
0.76
"Once-daily application of paricalcitol ointment was safe and effective for the treatment of plaque psoriasis."( Topical paricalcitol (19-nor-1 alpha,25-dihydroxyvitamin D2) is a novel, safe and effective treatment for plaque psoriasis: a pilot study.
Durakovic, C; Holick, MF; Ray, S, 2004
)
1.06
"We confirm that paricalcitol suppresses iPTH and lowers proteinuria in patients with stage 2-5 CKD without an increased risk of adverse events."( Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis.
Chen, J; Cheng, J; Li, X; Zhang, W; Zhang, X, 2012
)
1.04
" Other adverse events were similar between groups."( Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism.
Ching, CH; Ghazali, A; Ghazalli, R; Goh, BL; Goh, HK; Manocha, AB; Mohamad, S; Narayanan, P; Omar, M; Ong, LM; Rahmat, K; Seman, MR; Shaariah, W; Shah, S; Vaithilingam, I, 2013
)
0.62
" Adverse events were higher in children who received placebo than in those administered paricalcitol during the double-blind treatment (88."( Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease.
Ariceta, G; Dell, KM; Dufek, MB; Eldred, A; Greenbaum, LA; Hoppe, B; Lee, HJ; Lerner, G; Linde, P; Warady, BA; Webb, NJA, 2017
)
0.99
" No significant differences were observed in the incidence of hypercalcemia, hyperphosphatemia, or adverse events."( A comparative analysis of the efficacy and safety of paricalcitol versus other vitamin D receptor activators in patients undergoing hemodialysis: A systematic review and meta-analysis of 15 randomized controlled trials.
Geng, X; Shi, E; Song, Y; Wang, S, 2020
)
0.81

Pharmacokinetics

This article reviews the pharmacokinetic characteristics of calcitriol, paricalcitol, and doxercalciferol. It also provides an overview of the metabolism of vitamin D.

ExcerptReferenceRelevance
" Compared with previous pharmacokinetic studies in HD patients, plasma concentrations (100 to 250 pg/mL) during the 4-hour period were consistent with predicted values for this dose, and there was no apparent increase in paricalcitol clearance during HD."( Effect of hemodialysis on the pharmacokinetics of 19-nor-1alpha,25-dihydroxyvitamin D2.
Cady, WW; Cato, A; Chang, M; Qasawa, B; Soltanek, C; Stoll, R, 1998
)
0.49
"02 ng/ml) and paricalcitol pharmacokinetic parameters were estimated using non-compartmental methods."( Effect of omeprazole on the pharmacokinetics of paricalcitol in healthy subjects.
Awni, W; Chan, J; Chira, T; Galitz, L; Palaparthy, R; Pradhan, RS; Rieser, M; Williams, LA, 2007
)
0.96
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" This post hoc analysis of a Phase 3 study evaluated the pharmacodynamic effects of the iron-based phosphate binder sucroferric oxyhydroxide (SFOH) and sevelamer (SEV) carbonate on VDRA activity in dialysis patients."( Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients.
Botha, J; Chong, EM; Covic, AC; Floege, J; Ketteler, M; Rastogi, A; Sprague, SM, 2016
)
0.43
" Potential interactions of SFOH and SEV with VDRAs were assessed using serum intact parathyroid hormone (iPTH) concentrations as a pharmacodynamic biomarker."( Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients.
Botha, J; Chong, EM; Covic, AC; Floege, J; Ketteler, M; Rastogi, A; Sprague, SM, 2016
)
0.43

Compound-Compound Interactions

The authors undertook a phase 1 study of gemcitabine in combination with escalating doses of paricalcitol administered weekly intravenously in patients with advanced cancers.

ExcerptReferenceRelevance
" Paricalcitol, when combined with As2O3, showed a markedly enhanced antiproliferative effect against acute myeloid leukemia (AML) cells."( 19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia.
Desmond, JC; Hewison, M; Hughes, SV; Koeffler, HP; Kumagai, T; O'Kelly, J; Shih, LY, 2005
)
1.24
"The authors undertook a phase 1 study of gemcitabine in combination with escalating doses of paricalcitol administered weekly intravenously in patients with advanced cancers."( A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies.
Fetterly, G; Fountzilas, C; Iyer, R; Javle, M; Johnson, C; Ma, Y; Tan, W, 2018
)
0.94

Bioavailability

ExcerptReferenceRelevance
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
"75 L/h and bioavailability of 75."( Exposure-clinical response analysis of paricalcitol in patients with chronic kidney disease (stage 5) on hemodialysis or peritoneal dialysis.
Awni, WM; Garimella, TS; Klein, CE; Lichtenberger, O; Noertersheuser, PA; Palaparthy, R; Pradhan, RS; Williams, LA, 2012
)
0.65
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Paricalcitol was dosed according to parathyroid hormone (PTH): 1mg/day for patients with PTH < 500 pg/ml, and 2mg/ day for those with higher PTH levels. Serum PTH remained suppressed during the dosing period, but tended to rebound in the paricalcito.

ExcerptRelevanceReference
" The study end point for efficacy was at least a 30% reduction from maximum baseline in iPTH level for 75% of the patients receiving paricalcitol per dosing group."( Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2.
Arruda, J; Delmez, J; Goldblat, MV; Keshav, G; Lau, A; Lindberg, JS; Llach, F; Sadler, R; Slatopolsky, E, 1998
)
0.5
" Time-course and dose-response studies on 1,25-(OH)(2)D(3) and 19-nor-1,25-(OH)(2)D(2) induction of the marker of bone formation, osteocalcin, showed overlapping curves."( Relative potencies of 1,25-(OH)(2)D(3) and 19-Nor-1,25-(OH)(2)D(2) on inducing differentiation and markers of bone formation in MG-63 cells.
Dusso, AS; Finch, JL; Pavlopoulos, T; Slatopolsky, EA, 2001
)
0.31
" Subsequent dosing was based on iPTH, calcium, and phosphorus determinations."( Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism.
Llach, F; Yudd, M, 2001
)
1.75
" We conducted a double-blind, double-dummy, randomized, 12-week, multicenter trial to compare the incidence of hypercalcemia (single occurrence) between two dosing regimens: one regimen based on baseline intact parathyroid hormone (iPTH; PTH/80) level, and the other regimen based on patient body weight (0."( Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study.
Amdahl, M; González, E; Lindberg, JS; Llach, F; Malhotra, K; Martin, KJ; Taccetta, C, 2001
)
1.75
" More aggressive paricalcitol dosing and close patient follow up was shown to be effective in the management of SHPT."( Severe secondary hyperparathyroidism.
Chmielewski, C; Foerster, D, 2001
)
0.65
"Treatment of hyperparathyroidism includes the use of 1,25-dihydroxy-vitamin D3 (1,25D3) to suppress parathyroid hormone (PTH), but dosing of 1,25D3 is limited by the development of hypercalcemia and a high calcium x phosphorus (Ca x P) product because of gut absorption of calcium and phosphorus and enhanced bone resorption."( Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients.
Ahya, SN; Coyne, DW; Giles, K; Grieff, M; Norwood, K; Slatopolsky, E, 2002
)
0.31
" Five different methods for dosing phosphate binders were determined."( The renal dietitian's role in managing hyperphosphatemia and secondary hyperparathyroidism in dialysis patients: a national survey.
Martin, CJ; Reams, SM, 2003
)
0.32
" Less frequent dosing would be more convenient, require less nursing time, and be an option in other dialysis modalities."( Once-weekly intravenous paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients.
Cheng, SC; Coyne, DW; Staniforth, ME, 2005
)
0.64
"Once-weekly dosing of paricalcitol is an effective option in treatment of secondary hyperparathyroidism."( Once-weekly intravenous paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients.
Cheng, SC; Coyne, DW; Staniforth, ME, 2005
)
0.95
"In patients on a maintenance dose of paricalcitol, dosing doxercalciferol at 55-60% of the paricalcitol dose results in comparable inhibition of PTH."( Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol.
Ghantous, W; Roberts, L; Schinleber, P; Sprague, SM; Zisman, AL,
)
0.64
" The capsule form of paricalcitol was developed to provide a convenient dosage form for patients with stages 3 and 4 CKD."( Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.
Abboud, H; Acharya, M; Andress, DL; Batlle, D; Coyne, D; Fadem, S; Levine, B; Qiu, P; Rosansky, S; Sprague, SM; Williams, L, 2006
)
2.1
" Two studies used a thrice-weekly dosing regimen and 1 study used a once-daily dosing regimen for 24 weeks."( Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.
Abboud, H; Acharya, M; Andress, DL; Batlle, D; Coyne, D; Fadem, S; Levine, B; Qiu, P; Rosansky, S; Sprague, SM; Williams, L, 2006
)
1.78
"Intermittent dosing of calcitriol for secondary hyperparathyroidism (SHPT) has been associated with greater parathyroid hormone (PTH) reduction with fewer calcemic and phosphatemic effects than daily (QD) dosing."( A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4.
Abboud, H; Anger, M; Batlle, D; Coyne, D; Hippensteel, R; Kavanaugh, A; Lunde, N; Melnick, JZ; Palaparthy, RV; Pradhan, RS; Qiu, P; Smolenski, O; Williams, LA, 2006
)
0.61
"Secondary analyses of three randomized, double-blind, placebo-controlled multicenter studies in stage 3 and 4 chronic kidney disease (CKD) patients with SHPT were performed to compare three times per week (TIW) with QD dosing of paricalcitol."( A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4.
Abboud, H; Anger, M; Batlle, D; Coyne, D; Hippensteel, R; Kavanaugh, A; Lunde, N; Melnick, JZ; Palaparthy, RV; Pradhan, RS; Qiu, P; Smolenski, O; Williams, LA, 2006
)
0.79
"Pharmacokinetics revealed similar steady state paricalcitol exposure between dosing regimens."( A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4.
Abboud, H; Anger, M; Batlle, D; Coyne, D; Hippensteel, R; Kavanaugh, A; Lunde, N; Melnick, JZ; Palaparthy, RV; Pradhan, RS; Qiu, P; Smolenski, O; Williams, LA, 2006
)
0.87
"QD dosing of paricalcitol capsules is as efficacious as TIW dosing in achieving the primary end point (2 consecutive > or = 30% reductions in PTH) in stage 3 and 4 CKD patients with SHPT."( A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4.
Abboud, H; Anger, M; Batlle, D; Coyne, D; Hippensteel, R; Kavanaugh, A; Lunde, N; Melnick, JZ; Palaparthy, RV; Pradhan, RS; Qiu, P; Smolenski, O; Williams, LA, 2006
)
0.98
"Treatment of secondary hyperparathyroidism (SHPT) includes use of calcitriol (1,25D(3)) to suppress parathyroid hormone (PTH), but dosing of 1,25D(3) is limited by the development of hypercalcemia and a high calcium x phosphorus (Ca x P) product due to gut absorption of calcium and phosphorus as well as enhanced bone resorption."( Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients.
Ahya, SN; Coyne, DW; Giles, K; Joist, HE; Norwood, K; Slatopolsky, E, 2006
)
0.57
" Data suggest that dosing should be gauged according to degree of SHPT."( Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients.
Abitbol, CL; Chandar, J; Nwobi, O; Seeherunvong, W; Strauss, J; Zilleruelo, G, 2006
)
1.78
" Uremic patients, however, suffer from severe deprivation of biological vitamin D effects, that puts them in need of highly dosed vitamin D in order to both ameliorate their bone status and to preserve their general and cardiovascular health."( Therapy of secondary hyperparathyroidism to date: vitamin D analogs, calcimimetics or both?
Cannella, G; Messa, P,
)
0.13
" It was hypothesized that the ratio of the administered paricalcitol dosage to serum PTH level discloses better the underlying dosage-survival association."( Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients.
Greenland, S; Kalantar-Zadeh, K; Kopple, JD; Kovesdy, CP; McAllister, CJ; Shinaberger, CS; van Wyck, D, 2008
)
1.01
"Higher weekly paricalcitol dosage per each unit of serum PTH seems to have an incremental association with greater survival in MHD patients."( Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients.
Greenland, S; Kalantar-Zadeh, K; Kopple, JD; Kovesdy, CP; McAllister, CJ; Shinaberger, CS; van Wyck, D, 2008
)
1.12
" There was a reduction in the dosage and in the number of patients who were treated with paricalcitol and sevelamer."( Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters.
Aires, I; Amaral, T; Borges, M; Cortez, J; Ferreira, A; Ferreira, C; Gil, C; Jorge, C; Matias, PJ, 2010
)
0.58
" It allows reduction of vitamin D deficiency, better control of mineral metabolism with less use of active vitamin D, attenuation of inflammation, reduced dosing of erythropoiesis-stimulating agents, and possibly improvement of cardiac dysfunction."( Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters.
Aires, I; Amaral, T; Borges, M; Cortez, J; Ferreira, A; Ferreira, C; Gil, C; Jorge, C; Matias, PJ, 2010
)
0.36
" The validated method was used for paricalcitol determination in a formal stability study of its pharmaceutical dosage form in preloaded syringes."( Validated stability-indicating HPLC method for paricalcitol in pharmaceutical dosage form according to ICH guidelines: application to stability studies.
Cabeza, J; Capitán-Vallvey, LF; Navas, N; Ortega, R; Salmerón, A,
)
0.67
"04) g/24 h with 6 patients not receiving any anti-RAS and 42 treated with a single agent, at low dosage in most cases."( Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: a prospective observational study.
Conte, G; De Nicola, L; Gorini, A; Minutolo, R; Russo, D, 2012
)
0.66
" Paricalcitol was dosed according to parathyroid hormone (PTH): 1mg/day for patients with PTH < 500 pg/ml, and 2mg/day for those with higher PTH levels."( Paricalcitol reduces proteinuria but does not modify peritoneal protein loss in patients on peritoneal dialysis.
Coronel-Aguilar, D; Fernández-Viña, A; González-Díaz, I; Núñez-Moral, M; Peláez-Requejo, B; Quintana-Fernández, A; Rodríguez-Suárez, C; Sánchez-Álvarez, JE, 2013
)
2.74
" The dosing of study drugs and phosphate binders in the IMPACT study may not reflect actual practice, and patients were followed for 28 weeks, while the treatment of SHPT is long-term."( Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients.
Ketteler, M; Khan, SS; Marshall, TS; Schumock, GT; Sharma, A, 2013
)
0.62
" This study examined efficacy and safety of two dosing regimens of selective vitamin D receptor activator paricalcitol."( Efficacy and initial dose determination of paricalcitol for treatment of secondary hyperparathyroidism in Chinese subjects.
Amdahl, M; Chen, N; Huang, Z; Jiang, G; Khan, S; Li, X; Lin, H; Liu, L; Qian, J; Wang, M; Xing, C; Yan, Y; Yu, X; Zuo, L, 2014
)
0.88
"Both EU and US PI paricalcitol dosing strategies effectively reduced iPTH levels in Chinese subjects with SHPT, with minimal impact on Ca and P levels."( Efficacy and initial dose determination of paricalcitol for treatment of secondary hyperparathyroidism in Chinese subjects.
Amdahl, M; Chen, N; Huang, Z; Jiang, G; Khan, S; Li, X; Lin, H; Liu, L; Qian, J; Wang, M; Xing, C; Yan, Y; Yu, X; Zuo, L, 2014
)
1
" Costs were estimated by examining the dosage of the study drug (paricalcitol or cinacalcet) and phosphate binders used by each participant during the trial."( Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA.
Johns, B; Khan, SS; Marshall, TS; Sharma, A, 2014
)
0.95
"On the basis of dosing and effectiveness data from US patients in the IMPACT SHPT study, we found that a regimen of intravenous paricalcitol was more cost effective than cinacalcet plus low-dose vitamin D in the management of iPTH in patients with SHPT requiring haemodialysis."( Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA.
Johns, B; Khan, SS; Marshall, TS; Sharma, A, 2014
)
0.92
"05 for both dosing strata) at Weeks 8, 16 and 28."( Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
Cozzolino, M; Goldsmith, D; Ketteler, M; Khan, S; Martin, KJ; Sharma, A, 2014
)
1.85
" Then paricalcitol was administered intraperitoneally to isoproterenol-injected rats at a dosage of 200 ng three times a week for 3 weeks."( Paricalcitol Attenuates Cardiac Fibrosis and Expression of Endothelial Cell Transition Markers in Isoproterenol-Induced Cardiomyopathic Rats.
Cheng, PW; Hsiao, M; Lai, CC; Liou, JC; Liu, CP; Lu, PJ; Lu, WH; Sun, GC; Tseng, CJ, 2016
)
2.36
"To investigate the effects of Vitamin D Analogs, paricalcitol and alphacalcidol, on hemoglobin levels and erythropoietin-stimulating agents' dosage in hemodialysis patients with chronic renal failure."( EFFECTS OF VITAMIN D ANALOGS ON ERYTHROPOIESIS-STIMULATING AGENT DASAGE AND SECONDARY ANEMIA IN HEMODIALYSIS PATIENTS.
Kaya, T; Nalbant, A; Sipahi, S; Varim, C; Yaylaci, S, 2016
)
0.69
" Serum PTH remained suppressed during the dosing period, but tended to rebound in the paricalcitol groups."( Vitamin D receptor agonist VS-105 directly modulates parathyroid hormone expression in human parathyroid cells and in 5/6 nephrectomized rats.
Chen, YW; Fukagawa, M; Kakuta, T; Kanai, G; Sawada, K; Wessale, JL; Wu-Wong, JR, 2017
)
0.68
" Intact parathyroid hormone (iPTH), total serum calcium (Ca), phosphate (P), dosage of intravenous (IV) paricalcitol (Zemplar®) were analyzed and discussed via retrospective analysis of the database during the treatment."( Efficacy and safety of intravenous paricalcitol treatment in Chinese hemodialysis patients: a real-world database analysis.
Jiang, G; Wang, N; Xie, Y, 2022
)
1.21
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antiparathyroid drugA drug used to treat hyperparathyroidism by reducing the excessive production of parathyroid hormones.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
seco-cholestane
hydroxy seco-steroid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency10.68220.000214.376460.0339AID720692
estrogen nuclear receptor alphaHomo sapiens (human)Potency21.94880.000229.305416,493.5996AID743069; AID743078; AID743079; AID743080; AID743091
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency16.16540.000323.4451159.6830AID743065; AID743067
Cellular tumor antigen p53Homo sapiens (human)Potency9.43920.002319.595674.0614AID651631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)Ki4,286.70021.19105.12919.9410AID1802951
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (146)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
pentose-phosphate shuntGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
lipid metabolic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
cholesterol biosynthetic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
NADP metabolic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
NADPH regenerationGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
glutathione metabolic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
pentose-phosphate shunt, oxidative branchGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
response to iron(III) ionGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
negative regulation of protein glutathionylationGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
response to organic cyclic compoundGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
pentose biosynthetic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
substantia nigra developmentGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
response to foodGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
cellular response to oxidative stressGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
erythrocyte maturationGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
regulation of neuron apoptotic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
response to ethanolGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
ribose phosphate biosynthetic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
glucose 6-phosphate metabolic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
negative regulation of cell growth involved in cardiac muscle cell developmentGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
positive regulation of calcium ion transmembrane transport via high voltage-gated calcium channelGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
negative regulation of reactive oxygen species metabolic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
glucose metabolic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (38)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
glucose-6-phosphate dehydrogenase activityGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
protein bindingGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
glucose bindingGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
identical protein bindingGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
protein homodimerization activityGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
NADP bindingGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (24)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
cytoplasmGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
cytosolGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
cytoplasmic side of plasma membraneGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
membraneGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
centriolar satelliteGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
intracellular membrane-bounded organelleGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
extracellular exosomeGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
cytosolGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (41)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID775183Agonist activity at VDR in 5/6 nephrectomized uremic Sprague-Dawley rat assessed as dose require to suppress serum PTH level administered 3 times per week for 12 days measured 24 hrs post last dose by ELISA2013Bioorganic & medicinal chemistry letters, Nov-01, Volume: 23, Issue:21
Synthesis of VS-105: A novel and potent vitamin D receptor agonist with reduced hypercalcemic effects.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID775181Toxicity in 5/6 nephrectomized uremic Sprague-Dawley rat assessed as dose require to cause hypercalcemia administered 3 times per week for 12 days measured 24 hrs post last dose2013Bioorganic & medicinal chemistry letters, Nov-01, Volume: 23, Issue:21
Synthesis of VS-105: A novel and potent vitamin D receptor agonist with reduced hypercalcemic effects.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID775182Induction of human HL60 cell differentiation after 4 days by NBT reduction assay2013Bioorganic & medicinal chemistry letters, Nov-01, Volume: 23, Issue:21
Synthesis of VS-105: A novel and potent vitamin D receptor agonist with reduced hypercalcemic effects.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID775186Therapeutic index, ratio for induction of hypercalcemia over suppression of serum PTH level in 5/6 nephrectomized uremic Sprague-Dawley rat2013Bioorganic & medicinal chemistry letters, Nov-01, Volume: 23, Issue:21
Synthesis of VS-105: A novel and potent vitamin D receptor agonist with reduced hypercalcemic effects.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1802951In Vitro Inhibition Assay from Article 10.3109/14756360903489581: \\Effects of some drugs on human erythrocyte glucose 6-phosphate dehydrogenase: an in vitro study.\\2010Journal of enzyme inhibition and medicinal chemistry, Dec, Volume: 25, Issue:6
Effects of some drugs on human erythrocyte glucose 6-phosphate dehydrogenase: an in vitro study.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (481)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's13 (2.70)18.2507
2000's147 (30.56)29.6817
2010's283 (58.84)24.3611
2020's38 (7.90)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 69.81

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index69.81 (24.57)
Research Supply Index6.42 (2.92)
Research Growth Index5.56 (4.65)
Search Engine Demand Index119.70 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (69.81)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials100 (19.38%)5.53%
Reviews82 (15.89%)6.00%
Case Studies15 (2.91%)4.05%
Observational7 (1.36%)0.25%
Other312 (60.47%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]